China Oncology ›› 2023, Vol. 33 ›› Issue (1): 61-70.doi: 10.19401/j.cnki.1007-3639.2023.01.007
• Review • Previous Articles Next Articles
CHEN Yingyao(), CHU Xiangling, YU Xin, SU Chunxia()
Received:
2022-08-24
Revised:
2022-10-24
Online:
2023-01-30
Published:
2023-02-13
Contact:
SU Chunxia
CLC Number:
CHEN Yingyao, CHU Xiangling, YU Xin, SU Chunxia. Advances in models predicting efficacy of immune checkpoint inhibitors[J]. China Oncology, 2023, 33(1): 61-70.
Tab. 1
Summary of ICI efficacy-related prediction models"
Author | Model type | Sample size | Data source | Research description | Validate |
---|---|---|---|---|---|
Bai, et al [ | Statistical model | NSCLC (n=316) | Tumor tissue | Developed a gene mutation marker model to predict the response of NSCLC patients to PD-1 inhibitor therapy | Internal+external |
Chowell, et al [ | Statistical model | NSCLC (n=538), melanoma (n=186), other (n=755) | Tumor tissue peripheral blood | Built a prognostic model based on genomics, clinical and demographic characteristics to predict the survival of patients receiving immunotherapy | Internal |
Gu, et al [ | Statistical model | HCC (n=365) | TCGA | Established a five-gene-based prognostic model based on the tumour immune microenvironment that can predict immunotherapy efficacy in HCC patients | Internal+external |
Dai, et al [ | Statistical model | HCC (n=365) | TCGA | Constructed an immune related gene based prognostic index, which can better predict the efficacy of immunotherapy for HCC patients | External |
Yi, et al [ | Statistical model | LUAD (n=497) | TCGA | Established a prognostic risk score model based on 17 immune related genes. Patients with low scores had a good prognosis after immunotherapy | Internal+external |
Hong, et al [ | Statistical model | Urothelial carcinoma(n=348) | EGA (EGAS#0000 1002556) | Built a risk stratification system based on 4 genes to predict the therapeutic response of ICIS in metastatic urothelial carcinoma | External |
Sun, et al [ | Statistical model | Kidney renal clear cell carcinoma (n=539) | TCGA | Established a prognostic risk scoring model based on six genes related to pyroptosis | Internal+external |
Zhang, et al [ | Statistical model | LUAD (n=1549) | TCGA | Conducted a comprehensive costimulatory molecule landscape analysis of patients with LUAD and built a model for prognosis and immunotherapy response prediction | Internal+external |
Xiang, et al [ | Statistical model | GC (n=6) | GEO (GSE112302) | Generate a prognostic risk score signature based on GC differentiation-related genes to predict overall survival | External |
Leader, et al [ | Statistical model | NSCLC (n=27) | Tumor tissue | Identified a cellular module called lung cancer activation model which is correlated with NSCLC response to immunotherapy | External |
Lu, et al [ | Statistical model | UCEC (n=488) | TCGA | Established a miRNA based diagnostic model and a prognostic model that can predict the prognosis and therapeutic responseof UCEC patients | Internal |
Gao, et al [ | Statistical model | GC (n=397) | TCGA | Built a prognostic model based on nine autophagy related lncRNA pairs for GC which can predict the efficacy of immunotherapy and chemotherapy | Internal |
Nabet, et al [ | Statistical model | NSCLC (n=99) | Peripheral blood | Built two predictive models through circulating tumor DNA and peripheral CD8 T cell levels | Internal+external |
Wei, et al [ | Statistical model | NSCLC (n=30), RCC (n=22), other (n=68) | Peripheral blood | Built a model based on dynamic peripheral blood immune cell markers monitoring | Internal |
Newell, et al [ | Statistical model | Melanoma (n=77) | Tumor tissue | Built a multivariable model combining the TMB and IFNg-related gene expression and robustly predicts response to immunotherapy | Internal+external |
He, et al [ | Statistical model | NSCLC (n=327) | CT | Developed an individual non-invasive biomarker that could distinguish high-TMB from low-TMB | Internal |
Mu, et al [ | Statistical model | NSCLC (n=697) | 18F-FDG PET/CT | Identified an effective and stable deeply learned score to measure PD-L1 expression status non-invasively | Internal+external |
Trebesch, et al [ | Statistical model | NSCLC (n=123), melanoma (n=80) | Contrast-enhanced CT | Provide a predictive machine learning model that could be used within the context of lesion response to treatment, patient treatment response, and response pattern characterization | Internal+external |
Liu, et al [ | Statistical model | NSCLC (n=46) | CT | Built a novel CT-based radiomics model that has the ability to predict the progression probability for patients with advanced NSCLC receiving nivolumab therapy | Internal |
Vaidya, et al [ | Statistical model | NSCLC (n=109) | CT | Developed a radiomic model using the integration of intratumoral and novel peritumoral texture and vessel tortuosity metrics | Internal+external |
Yang, et al [ | Statistical model | NSCLC (n=200) | CT | Offer a model which use multidimensional serial information with inputs from pretreatment clinical data, laboratory tests, and radiomics combined with deep learning | Internal |
Yang, et al [ | Statistical model | NSCLC (n=149) | CT | Established a radiomics model by combining CT image features and clinicopathological factors to predict the prognosis of immunotherapy | Internal |
Dercle, et al [ | Statistical model | Melanoma (n=575) | CT | Offer a prognostic model based on CT images at baseline and on first follow-up | Internal |
Nardone, et al [ | Statistical model | NSCLC (n=59) | CT | Built a model based on texture analysis to select NSCLC patients who may benefit by Nivolumab treatment | External |
Hinata, et al [ | Statistical model | GC (n=408) | Tumor tissue | Constructed a deep learning model based on tumor histopathological images to effectively stratify GC patients receiving immunotherapy | Internal+external |
Butner, et al [ | Mathe matical model | Present a mechanistic mathematical model of ICIs therapy to address the oncological need for early, broadly applicable readouts of patient response to immunotherapy |
[1] |
RIBAS A, WOLCHOK J D. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382): 1350-1355.
doi: 10.1126/science.aar4060 pmid: 29567705 |
[2] |
VADDEPALLY R K, KHAREL P, PANDEY R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence[J]. Cancers (Basel), 2020, 12(3): 738.
doi: 10.3390/cancers12030738 |
[3] |
ZHANG Y Y, ZHANG Z M. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol, 2020, 17(8): 807-821.
doi: 10.1038/s41423-020-0488-6 pmid: 32612154 |
[4] |
ZHU S M, ZHANG T, ZHENG L, et al. Combination strategies to maximize the benefits of cancer immunotherapy[J]. J Hematol Oncol, 2021, 14(1): 156.
doi: 10.1186/s13045-021-01164-5 |
[5] |
GALLUZZI L, HUMEAU J, BUQUÉ A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2020, 17(12): 725-741.
doi: 10.1038/s41571-020-0413-z |
[6] |
ROBERT C, RIBAS A, SCHACHTER J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(9): 1239-1251.
doi: S1470-2045(19)30388-2 pmid: 31345627 |
[7] |
O’DONNELL J S, TENG M W L, SMYTH M J. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167.
doi: 10.1038/s41571-018-0142-8 pmid: 30523282 |
[8] |
KALBASI A, RIBAS A. Tumour-intrinsic resistance to immune checkpoint blockade[J]. Nat Rev Immunol, 2020, 20(1): 25-39.
doi: 10.1038/s41577-019-0218-4 pmid: 31570880 |
[9] |
WANG Y, TONG Z, ZHANG W H, et al. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients[J]. Front Oncol, 2021, 11: 683419.
doi: 10.3389/fonc.2021.683419 |
[10] |
ZHOU C B, ZHOU Y L, FANG J Y. Gut microbiota in cancer immune response and immunotherapy[J]. Trends Cancer, 2021, 7(7): 647-660.
doi: 10.1016/j.trecan.2021.01.010 |
[11] |
AHN S, CHUNG Y R, SEO A N, et al. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer[J]. PLoS One, 2020, 15(5): e0233037.
doi: 10.1371/journal.pone.0233037 |
[12] |
ZHANG Q, LUO J, WU S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J]. Cancer Discov, 2020, 10(12): 1842-1853.
doi: 10.1158/2159-8290.CD-20-0047 pmid: 32816849 |
[13] |
DOROSHOW D B, BHALLA S, BEASLEY M B, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2021, 18(6): 345-362.
doi: 10.1038/s41571-021-00473-5 pmid: 33580222 |
[14] |
ZOUEIN J, KESROUANI C, KOURIE H R. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare[J]. Immunotherapy, 2021, 13(12): 1053-1065.
doi: 10.2217/imt-2020-0336 pmid: 34190579 |
[15] |
COLLINS G S, REITSMA J B, ALTMAN D G, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement[J]. J Clin Epidemiol, 2015, 68(2): 134-143.
doi: 10.1016/j.jclinepi.2014.11.010 pmid: 25579640 |
[16] |
STEYERBERG E W, MOONS K G M, VAN DER WINDT D A, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research[J]. PLoS Med, 2013, 10(2): e1001381.
doi: 10.1371/journal.pmed.1001381 |
[17] |
GRAY E P, TEARE M D, STEVENS J, et al. Risk prediction models for lung cancer: a systematic review[J]. Clin Lung Cancer, 2016, 17(2): 95-106.
doi: 10.1016/j.cllc.2015.11.007 pmid: 26712102 |
[18] |
KAMATH P S, WIESNER R H, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470.
doi: 10.1053/jhep.2001.22172 pmid: 11172350 |
[19] |
BAI X, WU D H, MA S C, et al. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study[J]. J Immunother Cancer, 2020, 8(1): e000381.
doi: 10.1136/jitc-2019-000381 |
[20] |
CHOWELL D, YOO S K, VALERO C, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types[J]. Nat Biotechnol, 2022, 40(4): 499-506.
doi: 10.1038/s41587-021-01070-8 |
[21] |
DAI Y F, QIANG W J, LIN K Q, et al. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2021, 70(4): 967-979.
doi: 10.1007/s00262-020-02743-0 pmid: 33089373 |
[22] |
GU X Y, GUAN J, XU J, et al. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes[J]. J Transl Med, 2021, 19(1): 26.
doi: 10.1186/s12967-020-02691-4 pmid: 33407546 |
[23] |
YI M, LI A P, ZHOU L H, et al. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma[J]. Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
doi: 10.1007/s00262-020-02817-z |
[24] |
HONG S, ZHANG Y M, CAO M M, et al. Hypoxic characteristic genes predict response to immunotherapy for urothelial carcinoma[J]. Front Cell Dev Biol, 2021, 9: 762478.
doi: 10.3389/fcell.2021.762478 |
[25] |
SUN Z L, JING C Y, GUO X D, et al. Comprehensive analysis of the immune infiltrates of pyroptosis in kidney renal clear cell carcinoma[J]. Front Oncol, 2021, 11: 716854.
doi: 10.3389/fonc.2021.716854 |
[26] |
ZHANG C Q, ZHANG Z H, SUN N, et al. Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma[J]. Oncoimmunology, 2020, 9(1): 1824641.
doi: 10.1080/2162402X.2020.1824641 |
[27] | XIANG R S, RONG Y P, GE Y H, et al. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer[J]. Aging (Albany NY), 2021, 13(4): 5928-5945. |
[28] |
LEADER A M, GROUT J A, MAIER B B, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J]. Cancer Cell, 2021, 39(12): 1594-1609.e12.
doi: 10.1016/j.ccell.2021.10.009 pmid: 34767762 |
[29] |
LU M, WU K H, TRUDEAU S, et al. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy[J]. Sci Rep, 2020, 10(1): 20575.
doi: 10.1038/s41598-020-77653-3 pmid: 33239757 |
[30] | GAO L, XUE J, LIU X M, et al. A risk model based on autophagy-related lncRNAs for predicting prognosis and efficacy of immunotherapy and chemotherapy in gastric cancer patients[J]. Aging (Albany NY), 2021, 13(23): 25453-25465. |
[31] |
NABET B Y, ESFAHANI M S, MODING E J, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition[J]. Cell, 2020, 183(2): 363-376.e13.
doi: 10.1016/j.cell.2020.09.001 pmid: 33007267 |
[32] |
WEI C, WANG M Y, GAO Q L, et al. Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2023: 72(1): 23-37.
doi: 10.1007/s00262-022-03221-5 |
[33] |
NEWELL F, PIRES DA SILVA I, JOHANSSON P A, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance[J]. Cancer Cell, 2022, 40(1): 88-102.e7.
doi: 10.1016/j.ccell.2021.11.012 |
[34] |
HE B X, DONG D, SHE Y L, et al. Predicting response to immunotherapy in advanced non-small cell lung cancer using tumor mutational burden radiomic biomarker[J]. J Immunother Cancer, 2020, 8(2): e000550.
doi: 10.1136/jitc-2020-000550 |
[35] |
MU W, JIANG L, SHI Y, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images[J]. J Immunother Cancer, 2021, 9(6): e002118.
doi: 10.1136/jitc-2020-002118 |
[36] |
TREBESCHI S, DRAGO S G, BIRKBAK N J, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers[J]. Ann Oncol, 2019, 30(6): 998-1004.
doi: S0923-7534(19)31202-5 pmid: 30895304 |
[37] |
LIU C, GONG J, YU H, et al. A CT-based radiomics approach to predict nivolumab response in advanced non-small cell lung cancer[J]. Front Oncol, 2021, 11: 544339.
doi: 10.3389/fonc.2021.544339 |
[38] |
VAIDYA P, BERA K, PATIL P D, et al. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade[J]. J Immunother Cancer, 2020, 8(2): e001343.
doi: 10.1136/jitc-2020-001343 |
[39] | YANG Y, YANG J C, SHEN L, et al. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small cell lung cancer[J]. Am J Transl Res, 2021, 13(2): 743-756. |
[40] |
YANG B, ZHOU L, ZHONG J, et al. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer[J]. Respir Res, 2021, 22(1): 189.
doi: 10.1186/s12931-021-01780-2 |
[41] |
DERCLE L, ZHAO B S, GÖNEN M, et al. Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis[J]. JAMA Oncol, 2022, 8(3): 385-392.
doi: 10.1001/jamaoncol.2021.6818 pmid: 35050320 |
[42] |
NARDONE V, TINI P, PASTINA P, et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab[J]. Oncol Lett, 2020, 19(2): 1559-1566.
doi: 10.3892/ol.2019.11220 pmid: 31966081 |
[43] |
HINATA M, USHIKU T. Detecting immunotherapy-sensitive subtype in gastric cancer using histologic image-based deep learning[J]. Sci Rep, 2021, 11(1): 22636.
doi: 10.1038/s41598-021-02168-4 pmid: 34811485 |
[44] |
BUTNER J D, ELGANAINY D, WANG C X, et al. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy[J]. Sci Adv, 2020, 6(18): eaay6298.
doi: 10.1126/sciadv.aay6298 |
[45] |
JI R R, CHASALOW S D, WANG L S, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab[J]. Cancer Immunol Immunother, 2012, 61(7): 1019-1031.
doi: 10.1007/s00262-011-1172-6 |
[46] |
JOHNSON D B, ESTRADA M V, SALGADO R, et al. Melanoma-specific MHC-Ⅱ expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy[J]. Nat Commun, 2016, 7: 10582.
doi: 10.1038/ncomms10582 |
[47] |
CHEN Q Y, ZHANG L, MO X K, et al. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2021, 49(1): 345-360.
doi: 10.1007/s00259-021-05509-7 |
[48] | WALSH R J, SOO R A. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies[J]. Ther Adv Med Oncol, 2020, 12: 1758835920937902. |
[49] |
BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249.
doi: 10.1146/annurev-pathol-042020-042741 pmid: 33197221 |
[50] |
HOGG S J, BEAVIS P A, DAWSON M A, et al. Targeting the epigenetic regulation of antitumour immunity[J]. Nat Rev Drug Discov, 2020, 19(11): 776-800.
doi: 10.1038/s41573-020-0077-5 |
[51] |
CHEN J F, WU P, XIA R, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy[J]. Mol Cancer, 2018, 17(1): 6.
doi: 10.1186/s12943-017-0756-y |
[52] |
KILGOUR E, ROTHWELL D G, BRADY G, et al. Liquid biopsy-based biomarkers of treatment response and resistance[J]. Cancer Cell, 2020, 37(4): 485-495.
doi: S1535-6108(20)30152-5 pmid: 32289272 |
[53] |
DERCLE L, CONNORS D E, TANG Y, et al. Vol-PACT: a foundation for the NIH public-private partnership that supports sharing of clinical trial data for the development of improved imaging biomarkers in oncology[J]. JCO Clin Cancer Inform, 2018, 2: 1-12.
doi: 10.1200/CCI.17.00137 pmid: 30652552 |
[54] |
SUN X Q, HU B. Mathematical modeling and computational prediction of cancer drug resistance[J]. Brief Bioinform, 2018, 19(6): 1382-1399.
doi: 10.1093/bib/bbx065 pmid: 28981626 |
[55] |
POLDRACK R A, HUCKINS G, VAROQUAUX G. Establishment of best practices for evidence for prediction: a review[J]. JAMA Psychiatry, 2020, 77(5): 534-540.
doi: 10.1001/jamapsychiatry.2019.3671 pmid: 31774490 |
[56] | BONNETT L J, SNELL K I E, COLLINS G S, et al. Guide to presenting clinical prediction models for use in clinical settings[J]. BMJ, 2019, 365: l737. |
[57] |
CHENG M L, PECTASIDES E, HANNA G J, et al. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions[J]. CA Cancer J Clin, 2021, 71(2): 176-190.
doi: 10.3322/caac.21650 |
[58] |
IGNATIADIS M, SLEDGE G W, JEFFREY S S. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5): 297-312.
doi: 10.1038/s41571-020-00457-x |
[59] |
HORVAT T Z, ADEL N G, DANG T O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center[J]. J Clin Oncol, 2015, 33(28): 3193-3198.
doi: 10.1200/JCO.2015.60.8448 pmid: 26282644 |
[1] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[2] | CHEN Yuguang, SUN Xiao, BI Zhao, QIU Pengfei, DUAN Baowei, FAN Qingda, WANG Yongsheng. Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation [J]. China Oncology, 2023, 33(2): 142-151. |
[3] | GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021 [J]. China Oncology, 2022, 32(9): 772-778. |
[4] | YU Hang, LIU Wensheng, ZHANG Ning, LIU Haikuan, CHEN Luohai, YAO Wang, FAN Wenzhe, LI Jiaping, CHEN Jie, WANG Yu. The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis [J]. China Oncology, 2022, 32(9): 794-799. |
[5] | ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei. Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma [J]. China Oncology, 2022, 32(9): 807-817. |
[6] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[7] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[8] | XU Yuchen, CHENG Leilei, WANG Yan, LIN Jinyi, CHEN Jiahui, CHEN Yifan, ZHOU Yuhong, LIU Tianshu, GE Junbo. Predictive value of sST2 level in immune-related adverse events [J]. China Oncology, 2022, 32(8): 712-718. |
[9] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
[10] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[11] | LIU Yanquan, HU Xiaomei, YIN Yue, LIN Lin, SHEN Jianzhen, CHEN Yuting, TANG Huanwen. A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder [J]. China Oncology, 2022, 32(7): 650-656. |
[12] | SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486. |
[13] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[14] | QU Yiping, HOU Peng. Genetic characteristics and prognosis of metastatic thyroid cancer in children [J]. China Oncology, 2022, 32(5): 373-379. |
[15] | SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis [J]. China Oncology, 2022, 32(4): 287-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd